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SUMMARY 
Background 
Phenytoin is the recommended second-line intravenous anticonvulsant to treat paediatric convulsive 
status epilepticus (CSE) in the UK. Some evidence suggests levetiracetam may be an effective and 
safer alternative. This trial compared the effectiveness and safety of these treatments in paediatric 
CSE. 
Methods 
This superiority, pragmatic, open-label randomised controlled trial was undertaken in 30 UK 
Emergency Departments with clinicians following national treatment algorithms. Consent was 
sought retrospectively (‘Research Without Prior Consent’) as CSE is a medical emergency. 
Participants were males and females, aged 6 months to <18 years, with CSE requiring second-line 
treatment, and were randomised (1:1) to receive levetiracetam (40 mg/kg over 5 minutes) or 
phenytoin (20 mg/kg over at least 20 minutes), stratified by centre. Primary outcome was time from 
randomisation to CSE-cessation. Statistical analysis adhered to a pre-specified strategy adopting the 
intention-to-treat principle. Trial Registration number: ISRCTN22567894. 
Findings 
Between 17th July 2015 and 7th April 2018, 286 participants were randomised and treated; 152 were 
allocated levetiracetam, and 134 phenytoin. CSE was terminated in 106 (70%) allocated 
levetiracetam, and 86 (64%) allocated phenytoin. Median time from randomisation to CSE-cessation 
was 35 minutes (IQR 20-NA) in the levetiracetam and 45 minutes (IQ 24-NA) in the phenytoin group 
(Hazard Ratio 1.17; 95% CI 0.87-1.57, p = 0.3). Results were robust to pre-specified sensitivity 
analyses including time from treatment commencement to CSE-cessation, and competing risks. One 
phenytoin-treated participant experienced serious adverse reactions. 
Interpretation 
Levetiracetam was not statistically superior to phenytoin in CSE-cessation rate, time taken to 
terminate CSE, or serious adverse reactions. However, the results, together with previously reported 
safety profiles and comparative ease of administration of levetiracetam, suggest it would be an 
appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment 
of paediatric CSE.    
Funding 
National Institute for Health Research (NIHR) Health Technology Assessment (HTA) programme. 
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INTRODUCTION 
Convulsive status epilepticus (CSE) is the most common neurological emergency of childhood.1 It has 
an annual incidence of 20 per 100,000 children, and is the second most common reason for 
unplanned admissions to Paediatric Intensive Care Units (PICU) in the UK.2 Mortality is low, but 
morbidity including neuro-disability, learning difficulties, and de novo and drug-resistant epilepsy, 
may be as high as 22%.3-6 The longer the duration of CSE, the more difficult it is to terminate, and the 
greater the morbidity risk.1,5,6  
CSE is treated using an algorithm recommended by Advanced Paediatric Life Support (APLS), which 
incorporates 10 minute intervals between treatments.7 Second-line treatment is given when CSE 
persists, either after two doses of benzodiazepine, or the child’s personalised emergency (rescue) 
treatment. Failure of second-line treatment is followed by anaesthesia via rapid sequence induction 
(RSI).7 Randomised controlled trial (RCT) evidence supports the use of benzodiazepines as first-line 
treatment.8 There is no high quality RCT evidence to support any second-line treatment.9 
The currently recommended second-line treatment of CSE in the UK and Europe is intravenous 
phenytoin (fosphenytoin in the USA) based on predominantly non-RCT data; reported cessation 
rates vary widely between 50% and 96%.10,11 Safety concerns are widely reported, particularly 
cardiovascular disturbance (hypotension and fatal arrhythmias) and Stevens Johnson syndrome.12-14 
Levetiracetam has been reported to be effective and well-tolerated in the management of serial 
seizures and CSE, also based on largely non-RCT data with reported CSE-cessation rates of between 
44 and 94%.9,11,15-17 Adverse reactions appear less frequent and less severe than with phenytoin.18 
Levetiracetam is administered more rapidly (five to 10 minutes) than phenytoin (a minimum of 20 
minutes), suggesting a more rapid termination of CSE may be possible. However findings of existing 
studies of second-line treatments cannot be generalised due to methodological issues, including 
small sample sizes and heterogeneity of primary outcomes. The management of CSE was therefore 
identified as one of five priority areas for research by the National Institute for Health and Care 
Excellence.  
The Emergency treatment with Levetiracetam or Phenytoin in convulsive Status Epilepticus in 
children (EcLiPSE) trial aimed to determine whether intravenous levetiracetam or intravenous 
phenytoin is the more effective and safer second-line anticonvulsant for the emergency 
management of childhood CSE. 
  
 
5 
METHODS 
Trial design 
An open-label parallel-randomised controlled trial was undertaken in 30 UK Emergency Departments 
(ED), all members of Paediatric Emergency Research in the United Kingdom & Ireland (PERUKI).19 
These included secondary care (district general hospitals) and tertiary centres. The trial protocol was 
published in 2017 and is also available from the funders in full 
(https://www.journalslibrary.nihr.ac.uk/programmes/hta/12127134/#/).20 
Participants  
Children of both sexes, aged 6 months to <18 years, presenting with CSE (generalised tonic-clonic, 
generalised clonic, or focal clonic) that required second-line treatment were eligible for inclusion. 
Patients were ineligible if they (i) presented with absence, myoclonic, or non-convulsive status 
epilepticus, or infantile spasms, (ii) were known or suspected to be pregnant, (iii) had a 
contraindication or allergy to levetiracetam or phenytoin, (iv) had established renal failure, (v) had 
received a second-line anticonvulsant during the presenting episode of CSE prior to screening, or (vi) 
were known to have been previously enrolled in EcLiPSE. 
The trial used Research Without Prior Consent (RWPC; ‘deferred consent’) due to the time-critical 
management of CSE, in accordance with regulatory requirements, RWPC guidance and pre-trial 
research.21,22 Parents/legal representatives/patients (hereafter participants) were approached once 
the child’s clinical condition was stable (ideally within 24 hours of randomisation, and prior to 
discharge from hospital), at which point written informed consent was sought to continue data 
collection and use data already collected.20 When consent was not sought prior to discharge, 
participants were contacted within five working days of randomisation by a member of the research 
team, and informed of the participant’s involvement and trial details. Participants were sent written 
information, a consent form, and a covering letter stating they had four weeks from the date of the 
letter to confirm or decline participation. We employed an ‘opt-out’ postal approach; the covering 
letter explained that the participant would be included in the trial if no response was received.  
Ethical approval was gained from the National Research Ethics Service (NRES), Liverpool Central, on 
the 3rd March 2016 (reference: 15/NW/0090); all participating centres were granted NHS permission 
prior to commencing recruitment. 
Randomisation and masking 
Participants were randomised to receive levetiracetam or phenytoin in a ratio of 1:1 using random 
variable block sizes of two and four. A computer generated randomisation schedule was produced 
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by an independent statistician, stratified by centre. Sites were provided with randomisation packs, 
which were sequentially numbered, heavy duty, opaque, A4 cardboard envelopes with tamper-proof 
closure strips to be opened in ascending order. Each envelope contained the random treatment 
allocation and relevant case report form (CRF). Periodic checks ensured sites had the correct number 
of envelopes, that they were intact, and that the sequential numbering system was maintained. 
Treating clinicians opened randomisation envelopes after confirmation of eligibility. This was 
undertaken following administration of the final first-line treatment to allow sufficient time to 
prepare and administer the allocated treatment in accordance with the APLS algorithm.7 Where CSE 
stopped prior to the administration of the randomised treatment, participants were excluded, but 
subsequently included if their seizure restarted and required a second-line treatment whilst in the 
ED. Team members were aware of the allocated drug, and the treating emergency clinician 
determined time of CSE cessation based on clinical examination. 
Procedures 
CSE management followed the APLS algorithm, and both study treatments were given 
intravenously.7,20 Levetiracetam was administered over five minutes in a dose of 40mg/kg (maximum 
dose 2·5 grams); phenytoin was administered over a minimum of 20 minutes in a dose of 20mg/kg 
(maximum dose 2 grams and with a maximum infusion rate of 1mg/kg/min). Clinicians treated 
subsequent ongoing CSE according to the APLS algorithm.7 
Data were recorded on a paper-based CRF by emergency clinicians during the CSE, including times of 
randomisation, commencement and completion of infusions, and cessation of CSE. These key data 
relating to the primary outcome were collated and highlighted on the first page of the CRF to ensure 
data accuracy. Additional information included participant demographics, CSE type, site of trial 
treatment administration, need for additional anticonvulsants, RSI, and adverse events (AE). 
Following consent, information was collected on pre-existing epilepsy diagnosis, oral maintenance 
anti-epileptic drugs, neurological co-morbidities, concomitant medications, aetiology of CSE, patient 
location on admission and at 24 hours, and further seizure activity within 24 hours. Final follow-up 
was undertaken 14 days following enrolment by chart review (recording discharge, readmission, 
death, and organ failure), and a brief participant postal questionnaire (exploring current participant 
health, new medical problems, and new antiepileptic medications). 
Outcomes 
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The primary outcome was time from randomisation to cessation of all visible signs of convulsive 
activity, defined as cessation of all continuous rhythmic clonic activity, as adjudged by the treating 
clinician. Electroencephalography (EEG) was not used. 
Secondary outcomes were (i) need for further anticonvulsants to manage the CSE following 
administration of the trial treatment, (ii) need for RSI due to ongoing CSE, (iii) need for admission to 
critical care, defined as either a high-dependency unit (HDU) or a PICU, and (iv) serious adverse 
reactions including death, airway complications, cardiovascular instability, extravasation injury, and 
extreme agitation. 
Statistical analysis 
The sample size was calculated based on existing reported seizure cessation rates for phenytoin and 
levetiracetam.10,18 140 randomised and consented participants per group, with a total of 183 events 
(CSE cessation) were required for a 0.05 level two-sided log-rank test for equality of survival curves 
to detect an increase in seizure cessation from 60% to 75% (a constant hazard ratio of 0.661) at 80% 
power. The sample size was increased to 308 to allow for 10% loss to follow up. The final sample size 
was 286 due to low attrition and completeness of primary outcome data. 
All randomised and consented participants who received a second-line treatment were included in 
the analysis according to their allocated treatment. Children who were randomised, but whose CSE 
stopped without requiring second-line treatment (and did not restart in the ED) were excluded 
(Figure 1). The safety analysis included the same participants grouped according to treatment 
received. To avoid double-counting, serious adverse events are reported separately to adverse 
events. 
A detailed statistical analysis plan was developed and is available in full 
(https://www.journalslibrary.nihr.ac.uk/programmes/hta/12127134/#/). The primary analysis was 
based on a modification to the intention-to-treat principle. Statistical tests were two-sided at a 5% 
significance level; results are presented with 95% confidence intervals. The primary outcome was 
analysed using the log-rank test and is presented with a Kaplan-Meier curve. All participants were 
followed up to CSE cessation, with censoring used in the event of RSI or death. Where an RSI was 
administered, time was censored at RSI plus 12 hours (720 minutes); in patients who died before CSE 
cessation, time was censored at time of death plus 48 hours (2880 minutes). Sensitivity analyses 
were conducted to consider the robustness of results to the analysis approach taken including (i) 
Gray’s test,23 treating RSI as a competing risk, (ii) time to CSE cessation calculated from infusion start 
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instead of randomisation, (iii) censoring participants at the time of an additional second-line 
treatment following failure to respond to the randomised treatment. 
Additional analysis using a Cox Proportional Hazards model adjusted for baseline characteristics of 
weight, gender, and whether this was the child’s first seizure. Two covariates (site of infusion and 
additional anticonvulsants given in parallel) specified in the analysis plan were not included as they 
were measured post-randomisation. In addition, centre could not be included in the Cox model due 
to lack of convergence. Schoenfeld residual plots were used to check the assumption of 
proportionality. The binary secondary outcomes of need for further anticonvulsants, RSI, and 
admission to critical care were analysed using the chi-square test, and presented with relative risks. 
Logistic regression models were fitted as additional analyses to the primary chi-square tests, with 
adjustments as per the Cox Proportional Hazards model. No adjustment was made for multiplicity 
for the secondary outcomes. Baseline categorical data and adverse event data are summarised using 
numbers and percentages, and continuous data as medians and inter-quartile ranges (IQR) as 
appropriate. 
All analyses were performed using SAS software, version 9·4. The trial was overseen by an 
Independent Data and Safety Monitoring Committee (IDSMC), which made recommendations to a 
Trial Steering Committee (TSC), which had an independent majority membership and remained blind 
to accumulating data until the trial end. The IDSMC and TSC met at least annually and were 
consulted prior to the decision to stop recruitment due to low attrition and completeness of data. 
The Haybittle-Peto approach was used by the IDSMC as a guide to consider stopping the trial within 
interim reports with 99.9% confidence intervals. The trial is registered with ISRCTN; 
ISRCTN22567894. 
Role of the funding source 
The trial funder monitored trial progress and approved oversight committee membership. They had 
no role in trial design, data collection, data analysis, data interpretation, or writing of the report. The 
corresponding author had full access to all data in the trial and had final responsibility for the 
decision to submit for publication. 
RESULTS 
The EcLiPSE trial opened to enrolment on 17th July 2015 (protocol version 3·0, 17/06/2015) and 
closed on 7th April 2018. Two hundred and eighty six participants were randomised and treated; 152 
(53%) with levetiracetam and 134 with (47%) phenytoin. Written consent was obtained in 250 (87%), 
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and the remaining (13%) were included via the ‘opt-out’ pathway. Participant flow is shown in Figure 
1. Baseline characteristics were consistent across groups (Table 1). 
CSE was terminated by levetiracetam in 106 (70%), and by phenytoin in 86 (64%) participants. Trial 
adherence data are shown in Table 2. Median time from randomisation to start of infusion was 11 
minutes (IQR 8-15) for levetiracetam and 12 minutes (IQR 8-17) for phenytoin. Infusion duration was 
longer than expected for 27 (18%) and 34 (25%) participants allocated to levetiracetam and 
phenytoin respectively. All participants, except two allocated phenytoin, received a full dose of trial 
treatment. 
For the primary outcome, median time from randomisation to seizure cessation was 35 minutes (IQR 
20-NA) in the levetiracetam group, and 45 minutes (IQR 24-NA) in the phenytoin group (log-rank test 
p=0·20) (Figure 2). Event times were censored for 46 (30%) and 48 (36%) levetiracetam and 
phenytoin participants respectively that received RSI for any reason prior to seizure cessation. The 
unadjusted hazard ratio was 1·2 (95% CI 0·91-1·6, p=0·2) in favour of levetiracetam. The Schoenfeld 
residuals for the unadjusted model (p=0·72) indicated the independency of time and the validity of 
the proportionality assumption. The Schoenfeld residuals for the adjusted model indicated that the 
assumption of proportionality for weight was not met (p=0·05, p-value range from 0·27 to 0·71 for 
other variables). The data were sub-grouped according to weight category as per the baseline table 
(<12kg, 12-36kg, >36kg) and estimates from the unadjusted and adjusted models calculated. The 
proportionality assumption within each subgroup of data was supported by the Schoenfeld 
residuals. Direction of treatment effect was consistent across subgroups, confidence intervals were 
wide, and results were not statistically significant. The non-significant treatment effect was 
increased for children in the >36kg subgroup, however numbers within this group are small. The 
results are provided in full in the supplementary material.  
Fifty-seven (38%) participants in the levetiracetam group and 50 (37%) in the phenytoin group 
received additional anticonvulsants (RR 1·01; 95% CI 0·7-1·4, p=0·97) (Table 3). Results were similar 
when restricted to the further management for the presenting episode of CSE. 
Forty-four (29%) participants in the levetiracetam group and 47 (35%) in the phenytoin group were 
given an RSI due to ongoing CSE (RR 0·83; 95% CI 0·59-1·16, p=0·27). (Table 3).  
Ninety-seven (64%) participants in the levetiracetam group and 72 (54%) in the phenytoin group 
were admitted to critical care (RR 1·19; 95% CI 0·97-1·45, p=0·08).  
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Safety data were analysed by treatment received (Table 4). One hundred and thirty two participants 
received levetiracetam, and 130 received phenytoin. The remaining 24 participants received both 
treatments sequentially; 17 received levetiracetam followed by phenytoin, and seven received 
phenytoin followed by levetiracetam. Twenty AEs were reported in 16 participants receiving 
levetiracetam, 23 AEs in 18 participants receiving phenytoin, and eight AEs in four participants 
receiving both treatments. Each individual AE had a prevalence of <10% (Table 4).  
Only five serious adverse events (SAEs) were observed (three in two participants receiving 
phenytoin, one in a participant receiving levetiracetam, and one in a participant who received both 
interventions). Four SAEs resolved; the remaining SAE occurred in a participant who died. The cause 
of death was catastrophic cerebral oedema unrelated to either treatment. This participant received 
levetiracetam followed by phenytoin. Two of the SAEs were assessed as having a relationship to 
treatment with one classed as a serious adverse reaction (SAR) and the other a suspected 
unexpected serious adverse reaction (SUSAR). The SAR was a case of hypotension considered to be 
immediately life-threatening and the SUSAR was a case of increased focal seizures and decreased 
consciousness considered to be medically significant. Both occurred in the same participant who was 
allocated and given phenytoin. 
Sensitivity analyses undertaken on the primary outcome confirmed the robustness of the results; 
these are provided in the supplementary material. 
DISCUSSION 
The EcLiPSE trial is the largest RCT to compare levetiracetam with phenytoin in the treatment of 
paediatric CSE unresponsive to first-line treatment. This trial, powered for superiority, did not detect 
a statistically significant difference in any outcome. The direction of effect favoured levetiracetam 
across the primary (time from randomisation to CSE cessation) and secondary outcomes (including 
the need for rapid sequence induction, and serious adverse reactions), other than for the secondary 
outcome of admission to critical care. These findings were robust in all sensitivity analyses. 
CSE cessation rates for levetiracetam (70%) and phenytoin (64%) were broadly similar to previously 
reported observational and retrospective adult studies.10,16 CSE cessation rates as high as 85-95% 
have been reported, though these studies display significant heterogeneity in design and 
outcomes.11,24 One RCT undertaken in adults with CSE compared the efficacy of intravenous 
phenytoin (20 mg/kg), valproate (30 mg/kg) and levetiracetam (25 mg/kg) in 150 patients 
unresponsive to intravenous lorazepam.17 CSE stopped in 34 (68%) patients treated with phenytoin, 
34 (68%) treated with valproate and 39 (78%) treated with levetiracetam (p = 0·44). A recent 
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paediatric RCT evaluated 100 children aged three to 12 years receiving levetiracetam (30mg/kg) or 
phenytoin (20mg/kg) if their CSE continued after one dose of intravenous diazepam.11 Efficacy was 
high and almost identical in both groups. A lower diastolic blood pressure was recorded in 
phenytoin-treated patients (p = 0·023). It is difficult to translate these findings to clinical practice due 
to the trial’s design, including many exclusion criteria, and primary outcome (absence of seizure 
activity within 24 hours).11 In UK practice, childhood CSE management follows the APLS algorithm, 
which is applicable to the vast majority of children presenting to EDs.7 Our study design therefore 
used eligibility criteria which were as inclusive as possible, and followed a treatment pathway that 
reflected clinical practice. 
We did not detect a statistically significant difference between levetiracetam and phenytoin in time 
to CSE cessation. A superiority design was selected for three reasons: (i) reported CSE cessation rates 
for each drug, hypothesising that levetiracetam would be more effective, (ii) the absence of RCT data 
comparing the effectiveness of either treatment to placebo, and (iii) the shorter infusion time of 
levetiracetam (5 minutes compared to at least 20 minutes for phenytoin). We selected time from 
randomisation, and instructed sites to undertake randomisation at the latest possible point which 
would allow reconstitution of the allocated treatment to provide scientific and clinical rigour. As the 
median time to commencement of infusion exceeded ten minutes in each arm, we also undertook a 
sensitivity analysis using time to cessation from commencement of infusion, which supported our 
primary analysis findings. 
Progression to RSI in CSE may be required for one or a combination of reasons including continuing 
CSE, respiratory depression, clinical deterioration, stability for transfer or to safely undertake 
investigations. However, RSI abolishes visible CSE activity, and may therefore prevent an assessment 
of CSE cessation directly related to trial treatment. Participants were therefore censored at the time 
of RSI but the censoring time was increased to allow for this to be a negative and potentially 
informative outcome. This may have artificially inflated the time to CSE cessation. However 
sensitivity analyses which censored patients at the time of RSI, and defined RSI as a competing risk, 
did not change our findings. 
Observed safety profiles were similar across both treatments. Due to their relative infrequency in 
relation to the trial population size, together with good clinical management in participating sites, 
low rates of serious adverse events or reactions were observed in EcLiPSE. However, hypotension, 
cardiac arrhythmias, and severe extravasation injuries are well-recognised adverse effects of 
phenytoin; rarely, the cardiovascular effects may be fatal.12-14 Levetiracetam was well tolerated 
when administered over five minutes, a more rapid rate than previously reported.16,17,25 Agitation 
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was the most common adverse event in the levetiracetam group, as reported previously.15 There 
were no new or unexpected serious adverse reactions with levetiracetam. Sedation, somnolence 
and dizziness are rare side effects in adults but this may in part reflect the prior use of 
benzodiazepines or craniotomy in the study population.18,26 
EcLiPSE is unique for many reasons. It is the first adequately powered RCT to compare the efficacy 
and safety of two anticonvulsants as second-line treatment for CSE. Second, it is the first adequately-
powered RCT to evaluate phenytoin as a second-line treatment for CSE, despite this drug’s place as 
first-choice, second-line treatment for over 50 years. Third, it incorporated a nested consent study 
that evaluated the process of RWPC in a paediatric emergency medicine trial.20 Fourth, it was the 
first multicentre RCT to be supported by and delivered across the then nascent Paediatric Emergency 
Research in the United Kingdom and Ireland (PERUKI) collaborative.19 
This trial has a number of strengths. First, it evaluated a specific step (second-line treatment) in a UK 
clinical algorithm for the management of childhood CSE.7 A similar trial assessing the first-line, non-
intravenous treatment of CSE in the same algorithm led to a change in national clinical practice.27 
Second, it demonstrated RWPC is acceptable and successful, with 385 of 404 (95%) randomised 
participants providing consent; in those who were randomised and treated, 286 of 311 (92%) 
provided consent. RWPC is essential for the successful delivery of paediatric emergency care trials. 
The high consent rate mirrors that found in a previous trial of first-line CSE management (consent 
rate, 97%)27, and in a pilot RCT that compared fluid boluses in shock (consent rate, 100%).28 Third, it 
was a pragmatic trial, and recorded only key primary and secondary outcomes in the resuscitation 
room. This approach, supported by focussed data-collection materials and simple allocation and 
enrolment methods, facilitated successful delivery of the study across all sites as shown by low 
numbers of missed patients, high protocol adherence and accurate data capture for key outcomes. 
Finally, the trial was conducted in EDs from secondary and tertiary institutions throughout PERUKI, 
increasing generalisability of our findings, and facilitating rapid dissemination and knowledge 
translation. 
This trial has some limitations. First, it was open. A double-blind design was considered too complex 
for most participating sites, in part because of the markedly different infusion rates of the two drugs, 
and within the context of the life-threatening nature of CSE. Second, there was likely subjectivity in 
the assessment of ‘cessation of all signs of continuous, rhythmic clonic activity’ as the clinical event 
for our primary outcome, rather than fixed time-points to assess CSE-cessation. Clearly, these two 
limitations may collectively increase the risk of bias. However, continual assessment of a child’s 
condition reflects ‘real life’ practice in a dynamic situation, in which clinicians constantly evaluate 
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and prepare for the next step in the treatment algorithm. Site training included a simulated 
demonstration of the endpoint to ensure an understanding of the key outcome measure for the 
trial. It would not have been feasible or pragmatic for each participant to undergo a video recording 
or an electroencephalogram (EEG) to determine CSE-cessation time more precisely. It is not possible 
to state definitively without EEG whether any patients developed non-convulsive status epilepticus. 
However treatment algorithms for non-convulsive status epilepticus would follow the same flow as 
CSE, and there was no difference between treatment groups in the number of additional 
anticonvulsants given after trial treatment. Third, the time-point of randomisation resulted in CSE 
terminating prior to administration of trial treatment in a number of cases; however this affected 
both treatment arms equally, and was essential to maintain high standards of clinical care and avoid 
treatment delays. Fourth, we included safety measures as key secondary outcomes due to previous 
reports of harm. However this trial was not powered to demonstrate difference in serious adverse 
reactions (a secondary outcome) between treatment groups given their low incidence rate. Finally 
we considered a superiority design was more appropriate for reasons given above. 
Other treatment-related factors may be relevant to the interpretation of our findings. These include 
the widespread use of levetiracetam as maintenance therapy for many childhood epilepsies because 
of its broad-spectrum activity and safety profile. In EcLiPSE trial participants, it was the most 
commonly used oral anti-epileptic drug at the time of presentation. Anecdotally, clinicians are 
reluctant to give a loading dose of phenytoin in CSE to children on oral maintenance phenytoin due 
to potential cardiovascular toxicity. There seemed to be no similar concerns for levetiracetam and 
there was no observed increase in adverse events when giving 40mg/kg to children already receiving 
maintenance levetiracetam. A significant minority of children that present in CSE for the first time 
are subsequently commenced on maintenance therapy. This is more likely to be with levetiracetam 
than phenytoin because of the latter’s adverse safety profile and complex pharmacokinetics. One 
observational study in adults showed 8% of patients treated with intravenous fosphenytoin for CSE 
were subsequently commenced on oral phenytoin, in contrast to 78% treated with intravenous 
levetiracetam that were subsequently commenced on oral levetiracetam.24 Ease of drug preparation 
and administration is also a factor in the management of CSE. Throughout EcLiPSE, levetiracetam 
was reported by clinical teams in the participating centres to be easier to prepare and administer 
than phenytoin due to the latter’s calculations performed in reconstituting the drug, the number of 
vials required, and procedures needed for its administration, observations supported by the 
literature.14,18,26 
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Treatment strategies in the management of CSE are evolving. This includes the increasing use of two 
or more second-line treatments in preference to the traditional practice of immediate progression to 
RSI after failure of the first second-line treatment. This was observed in 35 participants in EcLiPSE. 
Clinicians may consider the risks of RSI greater than the administration and assessment of a second 
second-line treatment. The shorter administration time of levetiracetam may appeal as a first choice 
agent, in contrast to 20 minutes (or more) for phenytoin. Finally, intravenous levetiracetam has been 
shown to be as effective (76%) as intravenous lorazepam (the current first choice first-line treatment 
of CSE) in terminating CSE in adults.25 This may justify further study.  
The EcLiPSE trial did not show that levetiracetam was superior to phenytoin in the rate of CSE 
cessation, the time taken to terminate CSE, or adverse reactions and events. However, the results, 
together with previously reported safety profiles and relative ease of administration of 
levetiracetam, suggest it would be an appropriate alternative to phenytoin as the first-choice, 
second-line anticonvulsant in the treatment of paediatric CSE. 
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RESEARCH IN CONTEXT (PANEL) 
Evidence before this trial 
There are minimal RCT data for the second-line anticonvulsant treatment of paediatric CSE. Most 
published evidence for both phenytoin (the current recommended first choice anticonvulsant 
outside the USA) and levetiracetam is anecdotal and retrospective, or based on adult studies, or 
both. Observational data have suggested levetiracetam may be more effective than phenytoin. Two 
small RCTs undertaken predominantly in adults and a recent paediatric RCT, using a range of 
methodologies and outcomes, found no statistically significant difference in CSE-cessation or CSE-
recurrence within 24 hours between these two anticonvulsants. 
Added value of this trial 
To our knowledge, this is the first robust and adequately powered RCT that has directly compared 
any anticonvulsant in the second-line treatment of paediatric CSE in an emergency setting. It is also 
the first RCT that has compared the efficacy and safety of levetiracetam and phenytoin in this 
paediatric neurological emergency. There was no statistical difference between the two 
anticonvulsants in any primary or secondary outcome although the direction of effect favoured 
levetiracetam across the primary and secondary outcomes of efficacy and safety. The safety profile 
was similar between treatments, in contrast to much existing observational evidence that has shown 
phenytoin to have a worse safety profile. 
Implications of all the available evidence 
Our results suggest that levetiracetam may be considered as an alternative treatment to phenytoin 
in the second-line management of paediatric CSE. Additional benefits for levetiracetam over 
phenytoin include its ease of preparation and administration, minimal interaction with anti-epileptic 
and non-epileptic medications, and easy conversion to oral maintenance therapy. Further RCT and 
meta-analysis data may help to confirm its potential role and replacement of phenytoin as the 
preferred first-choice, second-line anticonvulsant in children with benzodiazepine-resistant CSE. 
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TABLES 
Table 1: Baseline demographic and seizure characteristics of the trial population 
 Levetiracetam 
n=152 (53%) 
Phenytoin 
n=134 (47%) 
Gender   
Male 75 (49%) 72 (54%) 
Female 77 (51%) 62 (46%) 
Age   
6 months - <2 years 65 (43%) 53 (40%) 
2-11 years 81 (53%) 74 (55%) 
12-17 years 6 (4%) 7 (5%) 
Median (IQR) 2·7 (1·3-5·9) 2·7 (1·6-5·6) 
Range 0·6-16·1 0·6-17·9 
Weight   
<12 kg 52 (34%) 42 (31%) 
12-36 kg 86 (57%) 80 (60%) 
>36 kg 14 (9%) 12 (9%) 
Median (IQR) 12·1 (10·0-19·0) 12·0 (10·0-18·0) 
Range 7·5-70·0 6·0-66·0 
Participant’s first seizure 69 (45%) 49 (37%) 
Presenting seizure type   
Generalised tonic-clonic 107 (70%) 105 (78%) 
Generalised clonic 12 (8%) 7 (5%) 
Focal clonic 33 (22%) 22 (16%) 
Seizure cause*   
Febrile convulsion 63 (41%) 58 (43%) 
Seizure (pre-existing epilepsy) 46 (30%) 46 (34%) 
First afebrile seizure  16 (11%) 12 (9%) 
Central nervous system infection 6 (4%) 7 (5%) 
Intracranial vascular event (bleed/stroke) 2 (1%) 2 (1%) 
Traumatic brain injury 0 0 
Substance misuse 1 (<1%) 0 
Indeterminate 10 (7%) 7 (5%) 
Other 27 (18%) 26 (19%) 
Maintenance anti-epileptic drugs at presentation*   
Levetiracetam 29 (15.9%) 26 (19.4%) 
Sodium Valproate 16 (10.5%) 19 (14.2%) 
Carbamazepine 12 (7.9%) 10 (7.5%) 
Clobazam 9 (5.9%) 9 (6.7%) 
Topiramate 4 (2.6%) 8 (6.0%) 
Phenytoin 0 (0.0%) 1 (0.7%) 
Other 11 (7.2%) 18 (13.4%) 
*categories not mutually exclusive 
 
  
 
23 
Table 2: Trial adherence data  
 Levetiracetam 
n=152 
Phenytoin 
n=134 
Total 
n=286 
Patient given lower dose of trial treatment 8 (5·3%) 4 (3·0%) 12 (4·2%) 
Patient given higher dose of trial treatment 2 (1·3%) 1 (0·8%) 3 (1·1%) 
Dose administration shorter than expected 0 (0·0%) 1 (0·8%) 1 (0·4%) 
Dose administration longer than expected 27 (17·8%) 34 (25·4%) 61 (21·3%) 
Treatment prematurely discontinued 0 (0·0%) 2 (1·5%) 2 (0·7%) 
Unauthorised route of administration (intraosseous) 6 (4·0%) 0 (0·0%) 6 (2·1%) 
Received initial second-line treatment other than that 
allocated 
3 (1·5%) 0 (0·0%) 3 (0·8%) 
Received further second-line treatment* 22 (14·5%) 13 (9·7%) 35 (13·6%) 
 *Includes those who subsequently received the alternative trial treatment, or an additional dose of allocated 
treatment, within 24 hours  
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Table 3: Secondary outcomes and 14 day follow-up 
 Levetiracetam 
N=152 
Phenytoin 
N=134 
  
Secondary outcomes N (%) N (%) Relative Risk 
(95% CI) 
p-value 
Need for further anticonvulsantsa 57  
(37·5%) 
50  
(37·3%) 
1·01  
(0·74-1·36) 
0·97 
Need for further anticonvulsants for 
the presenting CSEb 
24 
(15·8%) 
20 
(14·9%) 
1·06 
(0·61-1·83) 
0·84 
Need for further anticonvulsants for a 
subsequent seizure (within 24 hours)b,c 
14 
(9·2%) 
17 
(12·7%) 
0·72 
(0·37-1·4) 
0·33 
RSI to terminate an ongoing seizure 44  
(30·0%) 
47  
(35·1%) 
0·83 
(0·59-1·16) 
0·27 
Admission to critical care 97  
(63·8%) 
72  
(53·7%) 
1·19  
(0·97-1·45) 
0·08 
Serious adverse reaction  0 2d   
14 day follow-up     
Discharged from hospital 145 (95·4%) 130 (97·0%)   
Readmitted to hospital 12 (7·9%) 10 (7·5%)   
Patient died 1 (0·7%) 1 (0·8%)   
Organ failure 1 (0·7%) 0 (0·0%)   
     
CI: Confidence interval; RSI: Rapid Sequence Induction; CSE: Convulsive Status Epilepticus; 
aIncludes all instances of further anticonvulsant being given in following 24 hours, including for the presenting 
seizure, subsequent seizures, or for prophylaxis 
b post hoc analysis. Assessment conducted without knowledge of the allocated intervention 
c excludes 9 participants where the data were unavailable 
d two events in 1 participant one of which was a suspected unexpected serious adverse reaction (SUSAR)  
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Table 4:  Adverse events  
 Levetiracetam 
N=132 
Phenytoin 
N=130 
Both drugs 
N=24 
Total 
N=286 
Adverse Event Events Patients Events Patients Events Patients Events Patients 
Agitation 11 
11 
(8·3%) 
4 
4 
(3·1%) 
0 
0 
(0·0%) 
15 
15 
(5·2%) 
Hypotension 2 
2 
(1·5%) 
3 
3 
(2·3%) 
1 
1 
(4·2%) 
6 
6 
(2·1%) 
Catheter site 
related 
1 
1 
(0·8%) 
1 
1 
(0·8%) 
3 
2 
(8·3%) 
5 
4 
(1·4%) 
Extravasation 0 
0 
(0·0%) 
4 
4 
(3·1%) 
1 
1 
(4·2%) 
5 
5 
(1·75%) 
Tachycardia 1 
1 
(0·8%) 
3 
3 
(2·3%) 
1 
1 
(4·2%) 
5 
5 
(1·75%) 
Rash 2 
2 
(1·5%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
3 
3 
(1·1%) 
Hypertension 0 
0 
(0·0%) 
2 
2 
(1·5%) 
0 
0 
(0·0%) 
2 
2 
(0·7%) 
Reaction to 
Ceftriaxone 
0 
0 
(0·0%) 
0 
0 
(0·0%) 
1 
1 
(4·2%) 
1 
1 
(0·4%) 
Confused 1 
1 
(0·8%) 
0 
0 
(0·0%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Decreased 
consciousness 
0 
0 
(0·0%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Hallucination 1 
1 
(0·8%) 
0 
0 
(0·0%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Infusion site 
erythema 
0 
0 
(0·0%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Mechanical 
ventilation 
complication 
0 
0 
(0·0%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Pallor 0 
0 
(0·0%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Stridor 0 
0 
(0·0%) 
0 
0 
(0·0%) 
1 
1 
(4·2%) 
1 
1 
(0·4%) 
Vomiting 0 
0 
(0·0%) 
1 
1 
(0·8%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Wheezing 1 
1 
(0·8%) 
0 
0 
(0·0%) 
0 
0 
(0·0%) 
1 
1 
(0·4%) 
Total 20 
16 
(12·1%) 
23 
18 
(13·9%) 
8 
4 
(16·7%) 
51 
38 
(13·3%) 
  
